...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient’s preferences for health scenarios associated with hepatitis?C and its treatment
【24h】

Patient’s preferences for health scenarios associated with hepatitis?C and its treatment

机译：患者对与丙型肝炎及其治疗有关的健康状况的偏爱

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and aim: Antiviral therapy with peg-interferon and ribavirin induces sustained virus eradication in 40%–80% of patients with chronic hepatitis C virus (HCV). We investigated patient views on their involvement in therapeutic decision making and on the desirability of disease and treatment-related outcomes.Methods: The control preferences and visual analog scales were administered in a pencil and paper format to a series of 45 patients in order to assess their decisional role, preferences for scenarios of HCV disease and antiviral treatment, and estimates of success required to recommend treatment.Results: The preferred decisional role of patients was passive in 26 (58%), collaborative in 12 (27%) and active in 7 (15%). Median preference scores ranged from 0.30 to 0.90 for scenarios of disease, from 0.05 to 0.80 for side effects and from 25% to 100% for estimates of benefit to recommend treatment.Conclusions: Our patients prefer to defer to the doctor the final decision in starting therapy in a context of shared decision making. Reported preferences for HCV scenarios are in the range discussed in the literature. The wide variability in the values attributed to side effects by patients with chronic hepatitis C as well as in expected probabilities of successful treatment suggests a need for decision analysis tailored to the individual patient.
机译：背景与目的：聚乙二醇干扰素和利巴韦林联合抗病毒治疗可在40％–80％的慢性丙型肝炎病毒（HCV）患者中持续根除​​病毒。我们调查了患者对他们参与治疗决策，疾病的期望程度以及与治疗相关的结果的看法。方法：以铅笔和纸质形式对45例患者进行了控制偏好和视觉模拟量表的评估，以评估结果：患者的首选决策作用是被动的（26％（58％），协作的12％（27％）和主动的）。 7（15％）。对于疾病情况，中位偏爱评分范围为0.30至0.90，对于副作用而言，中位偏爱评分范围为0.05至0.80，对于推荐治疗的获益估计范围为25％至100％。结论：我们的患者更愿意将最终决定权交给医生共同决策的背景下进行治疗。报告的HCV方案偏好在文献中讨论的范围内。归因于慢性丙型肝炎患者的副作用以及成功治疗的预期可能性所造成的数值差异很大，这表明需要针对具体患者进行决策分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号